Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report) insider Hanlin Gao sold 1,673 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total transaction of $32,891.18. Following the transaction, the insider owned 986,117 shares of the company’s stock, valued at approximately $19,387,060.22. This represents a 0.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Hanlin Gao also recently made the following trade(s):
- On Thursday, August 27th, Hanlin Gao sold 939 shares of Fulgent Genetics stock. The stock was sold at an average price of $19.91, for a total value of $18,695.49.
Fulgent Genetics Price Performance
Shares of NASDAQ FLGT traded down $0.39 during mid-day trading on Thursday, hitting $19.65. 283,530 shares of the company’s stock traded hands, compared to its average volume of 233,486. Fulgent Genetics, Inc. has a 1 year low of $13.46 and a 1 year high of $31.04. The company’s 50-day moving average is $19.71 and its two-hundred day moving average is $18.01. The company has a market capitalization of $540.57 million, a P/E ratio of -6.97 and a beta of 0.93.
Analyst Upgrades and Downgrades
Several research analysts have commented on the stock. Piper Sandler lifted their price objective on shares of Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Wall Street Zen upgraded shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Finally, Weiss Ratings raised shares of Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $27.50.
View Our Latest Report on FLGT
Hedge Funds Weigh In On Fulgent Genetics
A number of large investors have recently bought and sold shares of FLGT. Moore Capital Management LP grew its position in Fulgent Genetics by 4.8% in the 2nd quarter. Moore Capital Management LP now owns 48,343 shares of the company’s stock valued at $992,000 after acquiring an additional 2,219 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Fulgent Genetics during the second quarter valued at $276,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Fulgent Genetics during the second quarter valued at $1,134,000. Almitas Capital LLC bought a new position in shares of Fulgent Genetics in the second quarter worth about $2,150,000. Finally, Corient Private Wealth LP purchased a new position in Fulgent Genetics in the 2nd quarter worth about $880,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.
Fulgent Genetics Company Profile
Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.
Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.
Featured Articles
- Five stocks we like better than Fulgent Genetics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
